1. Home
  2. WAY vs PTGX Comparison

WAY vs PTGX Comparison

Compare WAY & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Waystar Holding Corp.

WAY

Waystar Holding Corp.

HOLD

Current Price

$21.05

Market Cap

5.0B

Sector

N/A

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$98.30

Market Cap

5.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAY
PTGX
Founded
1999
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.2B
IPO Year
2023
2016

Fundamental Metrics

Financial Performance
Metric
WAY
PTGX
Price
$21.05
$98.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
17
13
Target Price
$36.59
$108.23
AVG Volume (30 Days)
2.3M
604.0K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
569.23
N/A
EPS
0.22
N/A
Revenue
$1,099,278,000.00
N/A
Revenue This Year
$18.26
$874.25
Revenue Next Year
$10.62
N/A
P/E Ratio
$97.23
N/A
Revenue Growth
16.50
N/A
52 Week Low
$20.35
$41.29
52 Week High
$41.96
$107.84

Technical Indicators

Market Signals
Indicator
WAY
PTGX
Relative Strength Index (RSI) 33.91 45.00
Support Level $21.03 $95.40
Resistance Level $27.12 $98.27
Average True Range (ATR) 1.31 3.83
MACD -0.30 -1.04
Stochastic Oscillator 11.21 10.94

Price Performance

Historical Comparison
WAY
PTGX

About WAY Waystar Holding Corp.

Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. Its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Share on Social Networks: